about
Safety of extended treatment with anakinra in patients with rheumatoid arthritisThe triterpenoid CDDO inhibits expression of matrix metalloproteinase-1, matrix metalloproteinase-13 and Bcl-3 in primary human chondrocytesAdvances in the treatment of cervical rheumatoid: Less surgery and less morbidityNew insights into the impact of neuro-inflammation in rheumatoid arthritisHow Rheumatoid Arthritis Can Result from Provocation of the Immune System by Microorganisms and VirusesTargeting Low Disease Activity in Elderly-Onset Rheumatoid Arthritis: Current and Future Roles of Biological Disease-Modifying Antirheumatic DrugsWhat is the impact of biologic therapies on common co-morbidities in patients with rheumatoid arthritis?Serious infections in patients with rheumatoid arthritis and other immune-mediated connective tissue diseases exposed to anti-TNF or rituximab: data from the Spanish registry BIOBADASER 2.0.Data-driven identification of co-morbidities associated with rheumatoid arthritis in a large US health plan claims databaseInfluenza and Pneumococcal Vaccination Uptake in Patients with Rheumatoid Arthritis Treated with Immunosuppressive Therapy in the UK: A Retrospective Cohort Study Using Data from the Clinical Practice Research Datalink.Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials.Development of a health care utilisation data-based index for rheumatoid arthritis severity: a preliminary studyWhy do people with rheumatoid arthritis still die prematurely?Does safety make a difference in selecting the right TNF antagonist?Perioperative management of drugs commonly used in patients with rheumatic diseases: a reviewPolycythemia Vera Management and Challenges in the Community Health Setting.Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry.TNF-α Antagonist and Infection in Rheumatoid Arthritis.Association of baseline steroid use with long-term rates of infection and sepsis in the REGARDS cohortInfections requiring hospitalization in the abatacept clinical development program: an epidemiological assessment.Tocilizumab in the treatment of rheumatoid arthritis: a cost-effectiveness analysis in the UK.[Factors associated with infection in rheumatoid arthritis].Risk of infections in bronchiectasis during disease-modifying treatment and biologics for rheumatic diseases.Evaluation of the RABBIT Risk Score for serious infectionsImpact of comorbidities on TNF inhibitor persistence in rheumatoid arthritis patients: an analysis of Korean National Health Insurance claims data.Vaccinations in patients with immune-mediated inflammatory diseasesRisk factors for total joint arthroplasty infection in patients receiving tumor necrosis factor α-blockers: a case-control study.Vaccinations for rheumatoid arthritis.Influenza and meningococcal vaccinations are effective in healthy subjects treated with the interleukin-1 beta-blocking antibody canakinumab: results of an open-label, parallel group, randomized, single-center study.Systematic review of validation studies of the use of administrative data to identify serious infections.Old drugs, old problems: where do we stand in prediction of rheumatoid arthritis responsiveness to methotrexate and other synthetic DMARDs?Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended studyDifferences between post-authorization adverse drug reactions of biopharmaceuticals and small molecules.The influence of systemic glucocorticoid therapy upon the risk of non-serious infection in older patients with rheumatoid arthritis: a nested case-control study.Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with speciaRates of serious intracellular infections in autoimmune disease patients receiving initial glucocorticoid therapy.Efficacy, safety and tolerability of tofacitinib in patients with an inadequate response to disease modifying anti-rheumatic drugs: a meta-analysis of randomized double-blind controlled studies.The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agentsChoice of Biologic Therapy for Patients with Rheumatoid Arthritis: The Infection Perspective.Assessing immune function by profiling cytokine release from stimulated blood leukocytes and the risk of infection in rheumatoid arthritis.
P2860
Q24675209-BC37EA07-4CB7-41A7-B83C-8DE92664B34DQ24797661-0888726B-7DF9-444F-952C-EC3F722DDE3FQ26825270-02F500C5-2514-42B2-AA76-B1541941FAE1Q27023946-5FB060F4-0AB8-4A1B-99FA-F19E1ACFD24DQ27468876-BED57576-263F-4B74-96D6-06C0786D535FQ28073436-B8C4B9AE-8916-4E82-AEA5-A21F68EC6BD2Q28074148-7CD07F04-BB0A-4B9F-B99B-6F50538485F1Q30731527-21C85C53-3302-4A3B-B317-E2950E79DD6DQ30990764-8B8A3E3D-888A-4321-8E1A-E74840FFA1A2Q31081624-98E59728-D59E-4C7F-A152-531124FAD85EQ33315300-1A16FB50-B030-42AF-A9D5-AB7AFCDA7E57Q33362177-C94E5AA8-6194-488D-BB1F-E98D8A5B47DEQ33697879-6BFBA05B-2F10-4C4F-B311-8A40AC7C4390Q33708863-DD58173F-1032-4E12-B721-ACE02B076C54Q33775870-86153E22-D3CB-45B9-9191-EC11EC020A38Q33803036-ABB65D06-02BB-4E5B-B3ED-536D80DE8F75Q33819684-1F5E78F9-C40B-4FB8-801F-2D13DFFADC72Q33872130-CB74F705-45F1-4E3D-A5F2-B41EBBC1F3BDQ33901429-6F4200D8-3697-440C-AF2D-32CA9C10F29FQ33923452-FD6188DD-91EA-4E55-BB98-70E937284446Q33962865-D0326055-4EEB-45C4-8280-6240E3F8566AQ34019646-73F118C8-E6FD-4D75-AF65-FE5A033F8B9FQ34065002-644EA2BD-A642-4B5D-8C85-EC5F872F3E15Q34092564-629022DB-304A-44E7-A923-9C8F59B9B21EQ34109394-EB74D895-7F5A-4E3A-8EE1-84878C0327EEQ34117134-20C0D145-6417-41F5-8772-DC3A5D0E9D9DQ34153015-611C51C3-6784-4EE0-A734-6E9F334CCC36Q34424563-7D998708-08AE-445E-97F5-FFB173F0DD18Q34431953-45DED63B-F6F5-48AD-8766-A9407217A58CQ34555474-5877FE60-8BCA-4C28-88A2-4309FBCE8771Q34559803-5910E59A-6A8F-4ABE-9B22-F7C1B848E3A1Q34562870-7AA5DB16-FB44-4811-B1A0-0953EE6EAB5AQ34582779-41AA467C-2369-449C-98A3-590F5B03F239Q34905686-72A815FE-1B8C-48B6-8DF6-56E36453028FQ35018415-AB445249-F158-4FC7-A645-E57EE83A0AA1Q35048101-17207FE9-BE79-4932-AA05-6CC64926289BQ35054330-2C1183B4-D1AD-4262-915A-97760567D6D9Q35082559-EE89152B-0D0B-4A54-B4D6-B3736D2FD033Q35237588-4FC5433A-31B4-47D4-8425-5B3A8B635359Q35242249-01D943EF-0318-4CBF-82A4-6A844C2BAEA2
P2860
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Predictors of infection in rheumatoid arthritis.
@en
type
label
Predictors of infection in rheumatoid arthritis.
@en
prefLabel
Predictors of infection in rheumatoid arthritis.
@en
P2093
P2860
P356
P1476
Predictors of infection in rheumatoid arthritis.
@en
P2093
Cynthia S Crowson
Gregory R Pond
Michele F Doran
Sherine E Gabriel
W Michael O'Fallon
P2860
P304
P356
10.1002/ART.10529
P577
2002-09-01T00:00:00Z